Sign in Subscribe

Archive

A collection of 715 issues

Latest

ctDNA Tracking May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery

Skip to content The CRC Digest ◆ TRIAL DATA ctDNA Tracking May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery The phase II GALAXY study showed that circulating tumor DNA monitoring for molecular residual disease could help identify which patients with colorectal cancer liver metastases are most likely to benefit from chemotherapy

Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA Predicts Recurrence Risk in Stage III Colorectal Cancer A systematic review and meta-analysis found that circulating tumor DNA (ctDNA) testing can help predict which stage III colorectal cancer patients are at higher risk of recurrence after surgery. (Clinical Colorectal Cancer)

CRC Research Update — August 02, 2026

Today's colorectal cancer research highlights

Evidence-Based Physical Activity Program Developed for Inactive CRC Survivors

Skip to content The CRC Digest Evidence-Based Physical Activity Program Developed for Inactive CRC Survivors Researchers used a Delphi process with 15 experts to develop a comprehensive physical activity promotion intervention for colorectal cancer survivors who do not meet recommended activity levels. (Asia-Pacific Journal of Oncology Nursing) This content is

Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients

Skip to content The CRC Digest ▸ TREATMENT Liquid Biopsy Detects ctDNA in 95% of Metastatic CRC Patients A Japanese single-center study using Guardant360 CDx found circulating tumor DNA in 18 of 19 metastatic colorectal cancer patients, with a median turnaround time of 11 days and pathogenic alterations identified in 79%

Surgery After Disease Progression May Still Benefit Select Liver Metastasis Patients

Skip to content The CRC Digest ▸ TREATMENT Surgery After Disease Progression May Still Benefit Select Liver Metastasis Patients A Japanese nationwide study analyzed patients from the Colorectal Cancer Liver Metastasis Database who received chemotherapy. (Annals of Surgical Oncology) This content is informational only and does not constitute medical advice. Always

Lean Body Mass Linked to Oxaliplatin Neuropathy Risk

Skip to content The CRC Digest ♥ LIVING WITH CRC Lean Body Mass Linked to Oxaliplatin Neuropathy Risk A study of colorectal cancer patients receiving adjuvant CAPOX found that lean body mass and sarcopenia may influence the risk of dose-limiting peripheral neuropathy, suggesting current body-surface-area dosing may not account for important

FDA Approves SimpleScreen CRC Blood-Based Screening Test

Skip to content The CRC Digest ● REGULATORY FDA Approves SimpleScreen CRC Blood-Based Screening Test The FDA has approved SimpleScreen CRC, a new blood-based screening test for colorectal cancer, expanding non-invasive screening options. (The ASCO Post) This content is informational only and does not constitute medical advice. Always consult your oncologist

CRC Research Update — August 01, 2026

Today's colorectal cancer research highlights

South Dakota sees shifting trends in early-onset CRC incidence by race

Skip to content The CRC Digest South Dakota sees shifting trends in early-onset CRC incidence by race Analysis of 2007-2022 cancer registry data shows the White population's early-onset CRC incidence rose to 9.6 per 100,000 in 2018-2022, surpassing the American Indian rate and reversing historical patterns.